Danek Group
This article was originally published in The Gray Sheet
Executive Summary
Spinal implant firm's proposed business combination with French firm Sofamor to form Sofamor/Danek Group calls for Danek to issue 6.5 mil. shares of its common stock to shareholders of Sofamor, according to an exchange ratio based on Danek's recent share price. Danek announced the deal with Sofamor, which also makes spinal implants, in March ("The Gray Sheet" April 5, p. 11). In addition, Danek will pay $6.8 mil. in cash to a dissenting Sofamor stockholder; 399,240 additional Danek shares also will be issued "to acquire certain intellectual property rights under a related purchase agreement." Danek says the total shares to be issued "will represent approximately 28.3% of Sofamor/Danek Group's outstanding shares after the combination." Danek shareholders will vote on the transaction at the annual meeting in Memphis, Tennessee on June 21.
You may also be interested in...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.